鲁索替尼乳膏(Ruxolitinib cream)不同版本一盒的最新价格公布

Introduction: Ruxolitinib Cream (Ruxolitinib cream) is an innovative Janus kinase (JAK) inhibitor. With the continuous advancement of medical technology and changes in market demand, the prices of different versions of ruxolitinib cream, including original drugs and generic drugs, have also become a focus of attention for patients and medical workers. The following will introduce the latest prices of the original drug and generic drug of ruxolitinib cream, and explain the types of drugs that need to be avoided when using this drug in combination.

Introduction to the prices of different versions of ruxolitinib cream

The latest price of a box of 60g of the original drug produced by Incyte in the United States is about $10,800. This price reflects the comprehensive costs of research and development, production, quality control and patent protection of the original drug.

Compared with the original drug, the generic ruxolitinib cream produced by Bangladesh Yaopin International is more affordable. The latest price for a box of 30g specifications is about $400. Generic drugs are similar to original drugs in terms of active ingredients, dosage forms, routes of administration and therapeutic effects, but their R&D and production costs are lower, making them more affordable.

Contraindications for combined use of ruxolitinib cream

Ruxolitinib cream is a powerful JAK inhibitor, so caution should be used when used in combination with other drugs. The following are some types of drugs that cannot be combined with ruxolitinib cream:

1. Therapeutic biologics: Since JAK inhibitors and therapeutic biologics may have overlapping or mutual interference in their mechanisms of action, it is not recommended to use ruxolitinib cream in combination with therapeutic biologics.

2. Other JAK inhibitors: Simultaneous use of multiple JAK inhibitors may increase the risk of adverse reactions, such as serious infections, malignant tumors, etc. Therefore, the combined use of ruxolitinib cream with other JAK inhibitors should be avoided.

3. Strong immunosuppressants such as azathioprine, cyclosporine and other strong immunosuppressants, combined with ruxolitinib cream may increase the risk of infection and other serious adverse reactions, so combined use should be avoided.

4. Drugs with potential interactions: In addition, patients should avoid taking ruxolitinib cream in combination with drugs with potential interactions. This includes, but is not limited to, certain antibiotics, antivirals, antifungals, etc. The specific types of contraindicated drugs should be determined based on the patient's specific situation and doctor's recommendations.